Literature DB >> 16038189

Identification and quantification of tamoxifen and four metabolites in serum by liquid chromatography-tandem mass spectrometry.

J Gjerde1, E R Kisanga, M Hauglid, P I Holm, G Mellgren, E A Lien.   

Abstract

We have developed a method for the determination of tamoxifen (tam) and its metabolites 4-hydroxytamoxifen (4OHtam), N-demethyltamoxifen (NDtam), N-dedimethyltamoxifen (NDDtam), tamoxifen-N-oxide (tamNox), and 4-hydroxy-N-demethyltamoxifen (4OHNDtam) in 50 microl human serum. Serum proteins were precipitated with acetonitrile. Deuterated-tamoxifen (D5 tam) was added as internal standard. Sample supernatant was injected into an on-line reversed-phase extraction column coupled with a C18 analytical column and analytes were detected by tandem mass spectrometry. The lower limits of quantification were 0.25 ng/mL for 4OHtam, NDtam and tam, 1.0 ng/mL for NDDtam and tamNox. Ranges of within- and between-day variation were 2.9-15.4% and 4.4-12.9%, respectively.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16038189     DOI： 10.1016/j.chroma.2005.01.004

Source DB:  PubMed          Journal:  J Chromatogr A        ISSN： 0021-9673            Impact factor:   4.759


  17 in total

1.  Characterization of the isomeric configuration and impurities of (Z)-endoxifen by 2D NMR, high resolution LC⬜MS, and quantitative HPLC analysis.

Authors:  Phyllis Elkins; Donna Coleman; Jason Burgess; Michael Gardner; John Hines; Brendan Scott; Michelle Kroenke; Jami Larson; Melissa Lightner; Gregory Turner; Jonathan White; Paul Liu
Journal:  J Pharm Biomed Anal       Date:  2013-07-24       Impact factor: 3.935

2.  Association of CYP2D6*10 (c.100C>T) polymorphisms with clinical outcome of breast cancer after tamoxifen adjuvant endocrine therapy in Chinese population.

Authors:  Lei Lei; Xian Wang; Xiao-Dan Wu; Zeng Wang; Zhan-Hong Chen; Ya-Bin Zheng; Xiao-Jia Wang
Journal:  Am J Transl Res       Date:  2016-08-15       Impact factor: 4.060

3.  Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women.

Authors:  Andrea Decensi; Chris Robertson; Aliana Guerrieri-Gonzaga; Davide Serrano; Massimiliano Cazzaniga; Serena Mora; Marcella Gulisano; Harriet Johansson; Viviana Galimberti; Enrico Cassano; Simona M Moroni; Franca Formelli; Ernst A Lien; Giuseppe Pelosi; Karen A Johnson; Bernardo Bonanni
Journal:  J Clin Oncol       Date:  2009-07-13       Impact factor: 44.544

Review 4.  High-performance liquid chromatography-tandem mass spectrometry in the identification and determination of phase I and phase II drug metabolites.

Authors:  M Holcapek; L Kolárová; M Nobilis
Journal:  Anal Bioanal Chem       Date:  2008-03-15       Impact factor: 4.142

5.  Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer.

Authors:  Jennifer Gjerde; Jürgen Geisler; Steinar Lundgren; Dagfinn Ekse; Jan Erik Varhaug; Gunnar Mellgren; Vidar M Steen; Ernst A Lien
Journal:  BMC Cancer       Date:  2010-06-21       Impact factor: 4.430

6.  CYP3A4 overexpression enhances apoptosis induced by anticancer agent imidazoacridinone C-1311, but does not change the metabolism of C-1311 in CHO cells.

Authors:  Monika Pawłowska; Ewa Augustin; Zofia Mazerska
Journal:  Acta Pharmacol Sin       Date:  2013-12-02       Impact factor: 6.150

7.  Steroid receptor coactivators, HER-2 and HER-3 expression is stimulated by tamoxifen treatment in DMBA-induced breast cancer.

Authors:  Line L Haugan Moi; Marianne Hauglid Flågeng; Jennifer Gjerde; Andre Madsen; Therese Halvorsen Røst; Oddrun Anita Gudbrandsen; Ernst A Lien; Gunnar Mellgren
Journal:  BMC Cancer       Date:  2012-06-15       Impact factor: 4.430

8.  Importance of highly selective LC-MS/MS analysis for the accurate quantification of tamoxifen and its metabolites: focus on endoxifen and 4-hydroxytamoxifen.

Authors:  N G L Jager; H Rosing; S C Linn; J H M Schellens; J H Beijnen
Journal:  Breast Cancer Res Treat       Date:  2012-03-03       Impact factor: 4.872

9.  Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment.

Authors:  Ernst A Lien; Håvard Søiland; Steinar Lundgren; Turid Aas; Vidar M Steen; Gunnar Mellgren; Jennifer Gjerde
Journal:  Breast Cancer Res Treat       Date:  2013-09-01       Impact factor: 4.872

10.  Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide.

Authors:  Jennifer Gjerde; Sara Gandini; Aliana Guerrieri-Gonzaga; Line L Haugan Moi; Valentina Aristarco; Gunnar Mellgren; Andrea Decensi; Ernst A Lien
Journal:  Breast Cancer Res Treat       Date:  2012-05-05       Impact factor: 4.872
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.